Literature DB >> 28850763

Understanding tamoxifen adherence in women with breast cancer: A qualitative study.

Zoe Moon1, Rona Moss-Morris1, Myra S Hunter1, Lyndsay D Hughes1.   

Abstract

OBJECTIVE: Non-adherence to tamoxifen is common in breast cancer survivors and is associated with poor clinical outcomes. This study aimed to understand womens' experiences of taking tamoxifen and to identify factors which may be associated with non-adherence.
DESIGN: A qualitative study using semi-structured interviews.
METHODS: Thirty-two breast cancer survivors who had been prescribed tamoxifen took part in interviews conducted face to face or over the telephone. They were transcribed verbatim and analysed using inductive thematic analysis with elements of grounded theory.
RESULTS: A key theme identified in the data was weighing up costs and benefits of treatment, which resulted in women falling into three groups; tamoxifen is keeping me alive, tamoxifen is not worth the reduced risk of recurrence, or conflicting beliefs about the harms and benefits of treatment. Additional themes were living with risk of recurrence and information & support.
CONCLUSIONS: Women who believed that the necessity of tamoxifen outweighed its costs were more likely to be adherent, whereas women who thought that the benefits did not outweigh the side effects were more likely to have discontinued. A third more ambivalent group believed strongly in the importance of treatment, but were struggling with side effects and were often non-adherent. Patients sometimes felt unsupported and discussed a need for more comprehensive information. To increase adherence, future research needs to explore ways to increase beliefs around tamoxifen necessity and how to help women cope with side effects. Statement of contribution What is already known on this subject? Non-adherence to tamoxifen is associated with increased risk of recurrence and mortality. Up to 50% of patients are non-adherent to tamoxifen by the fifth year of treatment Few consistent predictors of tamoxifen non-adherence have been identified. What does this study add? Many women report not knowing how to manage their side effects. Non-adherence is related to how women weigh up their side effects against their medication beliefs. Interventions aiming to increase necessity beliefs and improve symptom management may be effective.
© 2017 The British Psychological Society.

Entities:  

Keywords:  adherence; breast cancer; medication beliefs; tamoxifen

Mesh:

Substances:

Year:  2017        PMID: 28850763     DOI: 10.1111/bjhp.12266

Source DB:  PubMed          Journal:  Br J Health Psychol        ISSN: 1359-107X


  9 in total

1.  Breast Cancer Survivors' Lived Experience of Adjuvant Hormone Therapy: A Thematic Analysis of Medication Side Effects and Their Impact on Adherence.

Authors:  Maryam Ibrar; Nicola Peddie; Sommer Agnew; Amanda Diserholt; Leanne Fleming
Journal:  Front Psychol       Date:  2022-05-06

2.  User acceptance of an app-based adherence intervention: Perspectives from patients taking oral anticancer medications.

Authors:  Eskinder Eshetu Ali; Sharlene Si Ling Chan; Jo Lene Leow; Lita Chew; Kevin Yi-Lwern Yap
Journal:  J Oncol Pharm Pract       Date:  2018-05-23       Impact factor: 1.809

3.  Use of Adjuvant Endocrine Therapy Among Post-Menopausal Breast Cancer Patients in Malaysia.

Authors:  Athirah Saiful Bahri; Tuan Mazlelaa Tuan Mahmood; Siti Azdiah Abdul-Aziz; Mohd Makmor-Bakry; Noraida Mohamed Shah
Journal:  Patient Prefer Adherence       Date:  2021-02-03       Impact factor: 2.711

4.  Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping guided by the Multiphase Optimisation Strategy.

Authors:  Sophie M C Green; David P French; Christopher D Graham; Louise H Hall; Nikki Rousseau; Robbie Foy; Jane Clark; Catherine Parbutt; Erin Raine; Benjamin Gardner; Galina Velikova; Sally J L Moore; Jacqueline Buxton; Samuel G Smith
Journal:  BMC Health Serv Res       Date:  2022-08-24       Impact factor: 2.908

5.  Both "Vitamin L for Life" and "One Milligram of Satan": A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer.

Authors:  Kirsti I Toivonen; Devesh Oberoi; Kathryn King-Shier; Katherine-Ann L Piedalue; Joshua A Rash; Linda E Carlson; Tavis S Campbell
Journal:  Curr Oncol       Date:  2021-07-05       Impact factor: 3.677

6.  Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study.

Authors:  Yiqi Pan; Sarah R Heisig; Pia von Blanckenburg; Ute-Susann Albert; Peyman Hadji; Winfried Rief; Yvonne Nestoriuc
Journal:  Breast Cancer Res Treat       Date:  2018-01-12       Impact factor: 4.872

7.  Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.

Authors:  Leah K Lambert; Lynda G Balneaves; A Fuchsia Howard; Stephen K Chia; Carolyn C Gotay
Journal:  BMC Cancer       Date:  2018-07-11       Impact factor: 4.430

8.  Development of a self-management intervention to improve tamoxifen adherence in breast cancer survivors using an Intervention Mapping framework.

Authors:  Zoe Moon; Rona Moss-Morris; Myra S Hunter; Lyndsay D Hughes
Journal:  Support Care Cancer       Date:  2020-10-29       Impact factor: 3.603

9.  Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer.

Authors:  Bertha Alejandra Martinez-Cannon; Andrea Castro-Sanchez; Regina Barragan-Carrillo; Sylvia de la Rosa Pacheco; Alejandra Platas; Alan Fonseca; Yoatzin Vega; Karen Bojorquez-Velazquez; Juan Enrique Bargallo-Rocha; Alejandro Mohar; Cynthia Villarreal-Garza
Journal:  Patient Prefer Adherence       Date:  2021-05-19       Impact factor: 2.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.